Boehringer Ingelheim Launches Flexible-Dosing PREVICOX Tablets for Dogs
Event summary
- Boehringer Ingelheim's PREVICOX (firocoxib) Chewable Tablets now feature a Quarterable Snap-Tab design, approved by the FDA on October 7, 2026.
- The new design allows for precise, customizable dosing for dogs as small as seven pounds, with quarterable 57 mg and 227 mg chewable tablets.
- Sustainability benefits include up to one month of storage for divided tablets and reduced packaging waste.
- The changes will be rolled out progressively through 2026 and 2027, starting with 227 mg x 60 count and 57 mg x 60 count presentations.
The big picture
Boehringer Ingelheim's new Quarterable Snap-Tab design for PREVICOX aligns with broader industry trends toward personalized veterinary care and sustainability. The flexible dosing options could enhance the drug's market position, particularly for smaller dogs, while the sustainability features may appeal to environmentally conscious consumers. This move underscores the company's focus on innovation in the animal health sector.
What we're watching
- Market Adoption
- How quickly veterinarians and dog owners will adopt the new flexible-dosing design.
- Competitive Response
- Whether competitors will introduce similar dosing flexibility features in their products.
- Sustainability Impact
- The extent to which the sustainability benefits influence purchasing decisions.
Related topics